Percepta: Early comparison of oral vs parenteral developability using basic properties

Description
While route-specific developability requires detailed data, basic predicted properties (solubility, lipophilicity, ionization) can provide a first-pass indication of whether a compound is more suited to oral or parenteral formulations.

Solution

1. For each compound, use Percepta to predict:
   • Aqueous solubility (logS).
   • logP/logD at physiological pH.
   • pKa values.
2. Qualitatively consider:
   • Oral: needs sufficient solubility and permeability, may tolerate higher lipophilicity but faces GI solubility and first-pass metabolism issues.
   • Parenteral (e.g., IV): often requires higher solubility or specialized enabling formulations; very high lipophilicity may be challenging.
3. Flag compounds that:
   • Have extremely low solubility and unfavorable logD for simple oral formulations.
   • Or, conversely, look hard to solubilize adequately for IV without complex formulations.
4. Use these flags in cross-functional discussions with formulation and DMPK teams to:
   • Decide which route to prioritize.
   • Plan early formulation feasibility work.
5. Emphasize that these are screening-level insights and must be complemented with experimental data.